drugset / Trial / NCT03754309

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

NCT03754309

Phase 2 Completed 89 enrolled Kymab Limited
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.

Timeline

Start
2018-12-13
Primary completion
2020-05-12
Completion
2020-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlitelimab Monoclonal antibody

Indications